Ajax Therapeutics Inc. has synthesized heterocyclic amide and urea compounds acting as tyrosine-protein kinase JAK2 inhibitors and thus reported to be useful for the treatment of cancer and myelofibrosis.

A Beijing Danatlas Pharmaceutical Technology Co. Ltd. patent describes tricyclic heterocyclic derivatives acting as membrane-associated tyrosine- and threonine-specific Cdc2-inhibitory kinase (PKMYT1) inhibitors reported to be useful for the treatment of cancer.

Despite promising preclinical data, most animal models fail to predict response to therapy in humans.

Lawrence Livermore National Laboratory, Leidos Biomedical Research Inc. and Theras Inc. have jointly disclosed new GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Work at Sonata Therapeutics Inc. has led to the creation of phospholipid hydroperoxide glutathione peroxidase, mitochondrial (PHGPx; GPX4) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.

Researchers from Bugworks Research Inc. presented the discovery and preclinical evaluation of a novel potent and selective cyclin-dependent kinase 7 (CDK7) inhibitor, BWC-5044, in development for the treatment of cancer.

Shanghai Huilun Pharmaceutical Co. Ltd. has patented proteolysis targeting chimeric compounds (PROTACs) comprising E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1)-binding moiety through a linker.

Nuvalent Inc. has disclosed new heteroaromatic macrocyclic ether compounds acting as proto-oncogene tyrosine-protein kinase ROS (ROS1; MCF3) and/or ALK tyrosine kinase receptor inhibitors potentially useful for the treatment of cancer.